ATOS insider transaction filings
ATOSSA THERAPEUTICS, INC. — 21 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-14. Screen ATOS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-14 | 4 | Chen Shu-Chih — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-05-14 | 4 | Remmel H. Lawrence — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-05-14 | 4 | Finn Jonathan — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-05-14 | 4 | Galli Stephen J — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-05-14 | 4 | Cigler Tessa — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-05-14 | 4 | Steinhart Richard I — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-03-31 | 4 | QUAY STEVEN C — President & CEO, Director | Grant/award (A): 65,000 @ $0 | EDGAR |
| 2026-03-30 | 4 | Daniel Mark James — Chief Financial Officer | Grant/award (A): 63,000 @ $0 | EDGAR |
| 2026-01-30 | 4/A | QUAY STEVEN C — President & CEO, Director | Grant/award (A): 331,674 @ $0 · Grant/award (A): 950,000 (derivative) @ $0.60 | EDGAR |
| 2026-01-22 | 4 | QUAY STEVEN C — President & CEO, Director | Grant/award (A): 325,203 @ $0 · Grant/award (A): 950,000 (derivative) @ $0.60 | EDGAR |
| 2025-10-21 | 4 | Daniel Mark James — Chief Financial Officer | Grant/award (A): 578,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | QUAY STEVEN C — President & CEO, Director | Purchase (P): 11,239 @ $0.88 | EDGAR |
| 2025-05-16 | 4 | Finn Jonathan — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Chen Shu-Chih — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Rees Heather — Chief Financial Officer | Grant/award (A): 543,785 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Galli Stephen J — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Remmel H. Lawrence — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Cigler Tessa — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Steinhart Richard I — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | QUAY STEVEN C — President & CEO, Director | Grant/award (A): 1,366,062 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Remmel H. Lawrence — Director | Purchase (P): 10,000 @ $0.70 | EDGAR |
Recent 8-K events — ATOSSA THERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-16 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-25 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-02-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-26 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ATOS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →